Cardiovascular adverse effects of newer antidepressants

被引：37

作者：

Mago, Rajnish ^{[1
]}

Tripathi, Neeta ^{[2
]}

Andrade, Chittaranjan ^{[3
]}

机构：

[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Human Behav, Mood Disorders Program, Philadelphia, PA 19107 USA

[2] Hamilton Cardiol Associates, Hamilton, NJ USA

[3] Natl Inst Mental Hlth & Neurosci, Dept Psychopharmacol, Bangalore 560029, Karnataka, India

来源：

EXPERT REVIEW OF NEUROTHERAPEUTICS | 2014年 / 14卷 / 05期

关键词：

electrocardiogram; antidepressants; selective serotonin reuptake inhibitors; adverse effects; side effects; blood pressure; orthostatic hypotension; QT interval; cardiovascular; serotonin-norepinephrine reuptake inhibitors; MAJOR DEPRESSIVE DISORDER; SEROTONIN-REUPTAKE INHIBITORS; QT INTERVAL PROLONGATION; PLACEBO-CONTROLLED TRIAL; ISCHEMIC-HEART-DISEASE; BLOOD-PRESSURE; DOUBLE-BLIND; SAFETY PROFILE; 5-HYDROXYTRYPTAMINE RECEPTORS; CORONARY-ARTERY;

D O I：

10.1586/14737175.2014.908709

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Newer antidepressants that are more selective in their neurotransmitter effects include the selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and others (agomelatine, bupropion, mirtazapine, reboxetine, vilazodone, vortioxetine). This article systematically reviews data from a variety of sources regarding the potential adverse effects of these medications on various cardiovascular parameters. Potential biochemical mechanisms by which these antidepressants may adversely affect the cardiovascular system are also discussed. Antidepressants that are associated with higher cardiovascular risk (SNRIs, reboxetine), lower risk (SSRIs), and without current evidence of cardiovascular risk (agomelatine, mirtazapine, vilazodone, vortioxetine) are identified. The FDA's recommendations regarding citalopram are organized and summarized, and situations with higher risk of cardiovascular adverse effects are identified.

引用

页码：539 / 551

页数：13

共 103 条

[41] A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression [J].

Howland, Robert H. .

DRUG SAFETY, 2011, 34 (09) :709-731

[42] Electrocardiogram changes and arrhythmias in venlafaxine overdose [J].

Isbister, Geoffrey K. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (05) :572-576

[43] Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose [J].

Isbister, GK ;

Bowe, SJ ;

Dawson, A ;

Whyte, IM .

JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 2004, 42 (03) :277-285

[44] 5-HT1Dβ receptor mediates the supersensitivity of isolated coronary artery to serotonin in variant angina [J].

Ishida, T ;

Hirata, K ;

Sakoda, T ;

Kanazawa, K ;

Kawashima, S ;

Akita, H ;

Yokoyama, M .

CHEST, 1998, 113 (01) :243-244

[45]

Ishida T, 2001, CIRCULATION, V103, P1289

[46] Antidepressant therapy in patients with ischemic heart disease [J].

Jiang, W ;

Davidson, JRT .

AMERICAN HEART JOURNAL, 2005, 150 (05) :871-881

[47] Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: Overview of 26 cases [J].

Jimmink, Afra ;

Caminada, Klaartje ;

Hunfeld, Nicole G. M. ;

Touw, Daan J. .

THERAPEUTIC DRUG MONITORING, 2008, 30 (03) :365-371

[48] A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder [J].

Katona, Cornelius ;

Hansen, Thomas ;

Olsen, Christina Kurre .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2012, 27 (04) :215-223

[49] 5-Hydroxytryptamine receptors in the human cardiovascular system [J].

Kaumann, Alberto J. ;

Levy, Finn Olav .

PHARMACOLOGY & THERAPEUTICS, 2006, 111 (03) :674-706

[50]

Kemp AH, 2010, BIOL PSYCHIAT, V67, P1067, DOI [10.1016/j.biopsych.2009.11.019, 10.1016/j.biopsych.2009.12.012]

← 1 2 3 4 5 6 7 8 9 10 →